ClinicalTrials.gg
CompletedNCT06076421Updated Sep 29, 2026

Equity Evaluation of Fact Boxes on Informed COVID-19 and Influenza Vaccination Decisions - Study Protocol

An interventional study of Fact box in COVID-19 and Influenza, sponsored by Harding Center for Risk Literacy. Completed at 1 site in Germany. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Harding Center for Risk Literacy · Not applicable, Interventional, and Health services research

How we know

Updated Sep 29, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
175
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 226 studies in COVID-19 with a site in Germany — 21 open to participants now, 27 under way, 7 of them phase 3. COVID-19 · Germany.

Enrollment
60th of 130
175 · median 135
Started
2023
with 4 others
No phase
35 of 226
3 open now
Registered
216th of 226
by date

Among the 226 studies in COVID-19 with a site in Germany, this one is the 60th largest by enrollment of the 130 interventional ones that give a count, is one of 5 that started in 2023, is one of 35 with no phase, and was the 216th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

21 of the 226 studies in COVID-19 with a site in Germany are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 226 studies in COVID-19 with a site in Germany, or all of them as a file.
02

Study summary

The study aims to evaluate whether evidence-based fact boxes on COVID-19 and influenza vaccination contribute to the decision making of laypeople from different social backgrounds in different educational settings (e.g. medical practices, outreach work). Furthermore, the study will investigate whether evidence-based fact boxes can contribute to more equitable health care by improving shared decision-making.

Read the detailed description

Background

Evidence-based health information (EBHI) and decision aids (DA) are key components for improving health care by enabling more people to make informed decisions. However, despite their overall effectiveness, there is a risk that only certain groups of the population will benefit from them. Because although they are target group oriented, the factors that lead to inequality in terms of shared and informed decision-making have not yet been sufficiently taken into account in their development process. For example, there are many patient-oriented materials written at an advanced level, which makes the materials less accessible to people with reading difficulties, lower education, health literacy or socioeconomic status (SES).

Evidence-based fact boxes have been shown to support informed decision-making. However, few studies have analysed how the boxes support decision-making in different social groups. Further, it is unclear whether fact boxes promote informed and shared decision making equally when implemented by health educators (HE) in different settings. Hence, there is a risk that fact boxes will only help less disadvantaged people to make informed health decisions.

Objective

In a Multi-center, cluster-randomised, cross-sectional study, the effectiveness of evidence-based fact boxes (intervention) compared with usual health education/care (control) on outcomes relevant to the decision to vaccinate will be investigated in people from different backgrounds in Germany.

Fact boxes on COVID-19 and influenza vaccination have been adapted in several steps to meet the information needs and requirements of the population. This included feedback from various public health stakeholders on a COVID-19 fact box implemented in Germany in January 2021 by a national Public Health institute, the identification of information needs and requirements of the population in Germany based on secondary data analyses, and testing of COVID-19 fact boxes in pre-studies in population-wide surveys with N=1,942 to N=6,056 respondents in Germany. The data basis and individual studies have been described in detail elsewhere.

The Influenza vaccination fact box was updated in 2021 based on current evidence and is available on the Harding Center website for older people (65 years and older) and for people aged 16 to 65. During cognitive interviews, simplified COVID-19 and Influenza vaccination fact boxes were first piloted with German-speaking laypeople and adapted based on their feedback. Visualized COVID-19 fact boxes were also piloted with Arabic-, Turkish- and Russian-speaking laypeople from disadvantaged neighbourhoods in Berlin. A visualized flu fact box is currently being piloted by the University of Erfurt with German-speaking lay people.

Main research question

Do disadvantaged people benefit to the same extent as non-disadvantaged people in terms of informed and shared decision-making from receiving COVID-19 and influenza vaccination fact boxes as opposed to standard vaccination communication in medical practices and outreach work (field settings)?

Research questions (RQ) and main hypotheses (HYP)

RQ1 Is the use of fact boxes more effective than standard vaccine communication (control condition) in the field?

Primary HYP

  1. Compared to standard vaccine communication, fact boxes will lead to higher vaccination knowledge.
  2. Compared to standard vaccine communication, fact boxes will lead to more vaccination intentions that are in line with attitudes and vaccination knowledge (informed vaccination intentions; operationalised based on the multidimensional construct of informed choice by Marteau et al. 2001).

Secondary HYP

  1. Compared to standard vaccine communication, fact boxes will improve risk perception.
  2. Compared to standard vaccine communication, fact boxes will increase patient involvement in medical decision making.
  3. Compared to standard vaccine communication, fact boxes will decrease decisional conflict.

RQ2 Are fact boxes as effective for people with disadvantaging factors as for those without factors associated with disadvantages?

Primary HYP

Compared to standard vaccine communication, fact boxes will lead to a greater alignment of knowledge, informed vaccination intentions, and accuracy of risk perception between:

  1. People with low and high education through fact boxes compared to usual care.
  2. People with problematic or inadequate and excellent or sufficient level of health literacy through fact boxes compared to usual care.
  3. Non-native (Arabic, Turkish and Russian speaking participants, only with low German skills) and native German speakers (including non-native speakers with high German skills), because the investigators not only provide information in the native language, but also tested it with these target groups.
  4. People with low and high reading literacy in different languages, because fact boxes are a complexity-reduced format of health information and the investigators tried to address accessibility through pilot testing with different groups.

RQ3 Does the use of fact boxes in outreach work promote more shared and informed decision-making than in regular health care settings?

HYP

a) Compared to standard vaccine communication fact boxes will more likely lead to more informed vaccination intentions and shared decisions in outreach work than in regular health care settings.

Explorative analyses

  1. The investigators will analyse the effect of fact boxes on knowledge, vaccination intentions, accuracy of risk perception between people with low and medium or high SSS through fact boxes compared to usual care.
  2. The investigators will analyse the effect of fact boxes on vaccination intentions, knowledge, risk perception, patient involvement, and decisional conflict among people with migration-related indicators (e.g., residential status, length of stay in Germany) compared to usual care, controlling for other factors describing the social situation (e.g., education, health literacy).
03

Conditions studied

  • COVID-19
  • Influenza

Keywords

  • health inequity
  • informed decision making
  • fact box
  • evidence-based health information
  • risk communication
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults of legal age with current residence in Germany and who speak Arabic, German, Russian, Turkish
  • People who are currently facing a decision about COVID-19 or influenza vaccination for themselves or a family member (e.g. caring relatives)
  • Informed online consent

Exclusion criteria

Exclusion Criteria:

  • Language other than Arabic, German, Russian, Turkish
  • People without a current vaccination decision
  • No
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
175 participants (actual)

Study arms

  • Experimental
    Evidence-based fact box on COVID-19 or influenza (intervention)

    Health educators (HE) will receive a flyer with a brief description of the study, a Quick Response-code (QR-code) and a link to an online survey, including either a fact box as tabular format or a visualization on the reverse side about COVID-19 or the flu vaccine to distribute to potential study participants. HE are free to decide if and how to use the fact boxes: whether during, before or after vaccination education, and who to target. Participants who receive the flyer from their HE can decide on their own to participate in the study by using the QR-code or link on the flyer.

    Other: Fact box

  • No intervention
    Usual education/care

    Study participants whose HE will be randomised to the control will receive the same flyer but without a fact box on the reverse side.

Interventions

  • OtherFact box

    Fact boxes provide a tabular or graphical overview of the benefits and harms of the COVID-19 or influenza vaccination through transparent risk communication. The fact boxes are available for two different age groups each: COVID-19 vaccination for people aged 18 to 59 and over 60, influenza vaccination for people aged 16 to 64 and over 65 in Arabic, German, Russian and Turkish.

06

What researchers measure

Primary outcomes

  1. Knowledge

    10 items: five items on basic knowledge of the disease (e.g. how is Corona or the flu contracted and what are the possible baseline risks) and uncertainty (e.g. quality of evidence), each with 4 possible answers, of which only one is correct. A further five questions that can only be answered through the fact box, including one question on the benefits of vaccination gist and three questions on the benefits and harms of vaccination verbatim. Responses will be graded according to the best available evidence in July 2023.

    Time frame: at T1 (initial survey; study period: 3-6 month)

  2. Informed vaccination intention

    Based on vaccination knowledge, a person's attitudes and vaccination intentions. Knowledge will be measured as described above. Attitudes will be measured using an 11-point Likert scale that captures the personal assessment of the balance between the potential benefits and risks of the respective vaccine. Vaccination intention will be measured by asking whether participants would have themselves or their relatives vaccinated at the next opportunity, on a scale of 1-5 (Definitely yes, probably yes, probably not, definitely not, I cannot yet say / am still undecided).

    Time frame: at T1 (initial survey; study period: 3-6 month)

Secondary outcomes

  1. Risk perception

    Based on a frequency format (Please imagine 10 people like yourself: How many of them will be re-infected with COVID-19 after a previous coronavirus infection if they come into contact with a person who is infected with the coronavirus variant XBB.1.5?; How many will contract influenza in a year if the virus is widespread?): Correct responses (reflected the best available evidence, which can be found in the fact boxes together with the medical references.

    Time frame: at T1 (initial survey; study period: 3-6 month)

  2. Decisional conflict

    The 4-item SURE (Sure of myself; Understand information; Risk-benefit ratio; Encouragement) screening test will be used (if yes: 1, if no: 0; a score of \< 4 is a positive result for decisional conflict)

    Time frame: at T1 (initial survey; study period: 3-6 month)

  3. Patient involvement in decision making

    Measured with the 9-item Shared Decision Making Questionnaire (SDM-Q-9). The instrument contains nine statements which are rated on a six-point Likert scale (from 0 'completely disagree' to 5 'completely agree').

    Time frame: at T1 (initial survey; study period: 3-6 month)

Other outcomes

  1. Health literacy

    Measured by using the established and validated 12-item Health Literacy Survey Questionnaire (HLS19-Q12), a short form questionnaire of the 47-item Health Literacy Survey Questionnaire (HLS19-Q47) for measuring comprehensive, general health literacy (HL) in general adult populations. After an introductory statement about handling health information, respondents are asked to choose one of four response categories to the 12 questions about how easy or difficult tasks related to handling health information are (with 4 'very easy', 3 'easy', 2 'difficult', 1 'very difficult').

    Time frame: at T1 (initial survey; study period: 3-6 month)

  2. Subjective socioeconomic status

    Will be assessed by using the MacArthur Scale of Subjective Social status (SSS), which measures the subjective perception of social position within society on a 10-point scale (with SSS low: 1-4, middle: 5-6, high: 7-10).

    Time frame: at T1 (initial survey; study period: 3-6 month)

07

Study locations

1 site
  • Harding Center for Risk Literacy, Faculty of Health Sciences Brandenburg, University of Potsdam
    Potsdam, Brandenburg 14482, Germany
08

References and documents

Publications

  • Adler NE, Epel ES, Castellazzo G, Ickovics JR. Relationship of subjective and objective social status with psychological and physiological functioning: preliminary data in healthy white women. Health Psychol. 2000 Nov;19(6):586-92. doi: 10.1037//0278-6133.19.6.586. PubMed 11129362 ↗
  • Pelikan JM, Link T, Strassmayr C, Waldherr K, Alfers T, Boggild H, Griebler R, Lopatina M, Miksova D, Nielsen MG, Peer S, Vrdelja M; HLS19 Consortium of the WHO Action Network M-POHL. Measuring Comprehensive, General Health Literacy in the General Adult Population: The Development and Validation of the HLS19-Q12 Instrument in Seventeen Countries. Int J Environ Res Public Health. 2022 Oct 29;19(21):14129. doi: 10.3390/ijerph192114129. PubMed 36361025 ↗
  • Kriston L, Scholl I, Holzel L, Simon D, Loh A, Harter M. The 9-item Shared Decision Making Questionnaire (SDM-Q-9). Development and psychometric properties in a primary care sample. Patient Educ Couns. 2010 Jul;80(1):94-9. doi: 10.1016/j.pec.2009.09.034. Epub 2009 Oct 30. PubMed 19879711 ↗
  • Legare F, Kearing S, Clay K, Gagnon S, D'Amours D, Rousseau M, O'Connor A. Are you SURE?: Assessing patient decisional conflict with a 4-item screening test. Can Fam Physician. 2010 Aug;56(8):e308-14. PubMed 20705870 ↗
  • Rebitschek FG, Ellermann C, Jenny MA, Siegel NA, Spinner C, Wagner GG. Fact boxes that inform individual decisions may contribute to a more positive evaluation of COVID-19 vaccinations at the population level. PLoS One. 2022 Sep 12;17(9):e0274186. doi: 10.1371/journal.pone.0274186. eCollection 2022. PubMed 36095020 ↗
  • Marteau TM, Dormandy E, Michie S. A measure of informed choice. Health Expect. 2001 Jun;4(2):99-108. doi: 10.1046/j.1369-6513.2001.00140.x. PubMed 11359540 ↗
  • Durand MA, Yen RW, O'Malley AJ, Schubbe D, Politi MC, Saunders CH, Dhage S, Rosenkranz K, Margenthaler J, Tosteson ANA, Crayton E, Jackson S, Bradley A, Walling L, Marx CM, Volk RJ, Sepucha K, Ozanne E, Percac-Lima S, Bergin E, Goodwin C, Miller C, Harris C, Barth RJ Jr, Aft R, Feldman S, Cyr AE, Angeles CV, Jiang S, Elwyn G. What matters most: Randomized controlled trial of breast cancer surgery conversation aids across socioeconomic strata. Cancer. 2021 Feb 1;127(3):422-436. doi: 10.1002/cncr.33248. Epub 2020 Nov 10. PubMed 33170506 ↗
  • Miller DP Jr, Spangler JG, Case LD, Goff DC Jr, Singh S, Pignone MP. Effectiveness of a web-based colorectal cancer screening patient decision aid: a randomized controlled trial in a mixed-literacy population. Am J Prev Med. 2011 Jun;40(6):608-15. doi: 10.1016/j.amepre.2011.02.019. PubMed 21565651 ↗
  • Ellermann C, Savaskan N, Rebitschek FG. Do summaries of evidence enable informed decision-making about COVID-19 and influenza vaccination equitably across more and less disadvantaged groups? Study protocol for a multi-centre cluster randomised controlled trial of 'fact boxes' in health and social care in Germany. BMJ Open. 2024 Nov 1;14(10):e083515. doi: 10.1136/bmjopen-2023-083515. PubMed 39486820 ↗

Individual participant data

Plan to share: Yes — All relevant data will be provided in the manuscript and supporting information or made available in a public repository after completion of the study.

Time frame: After completion of the study.

Access criteria: All relevant data will be provided in the manuscript and supporting information or made available in a public repository (e.g., OSF) after completion of the study.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Mar 2025, 16 months.

Of 1,337 non-industry interventional studies with no phase under COVID-19, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's 16 months is above that.

Counting every sponsor, half of 1,475 studies reached it within 9 months; a quarter within 3 and three quarters within 19.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 29, 2026: primary completion Nov 2024 → Mar 2025 and completion Dec 2024 → May 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2023
First posted
Oct 10, 2023
StartActual
Nov 17, 2023
Primary completionActual
Mar 31, 2025was Nov 2024
CompletionActual
May 30, 2025was Dec 2024
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Sep 29, 2026
Primary completion
Nov 2024→Mar 31, 2025 (actual)
Sep 29, 2026
Study completion
Dec 2024→May 30, 2025 (actual)
Sep 29, 2026
Enrollment
800 (estimated)→175 (actual)
Sep 29, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 39486820 ↗
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Recruiting→Completed
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 39486820 ↗
    Primary completion Nov 2024→Mar 31, 2025 (now actual)
    Study completion Dec 2024→May 30, 2025 (now actual)
    Enrollment 800 (estimated)→175 (actual)
    + 4 other changes: index terms, verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06076421
Lead sponsor
Harding Center for Risk Literacy
Responsible party
Felix G. Rebitschek (Head Research Scientist and CEO, Harding Center for Risk Literacy) — Principal investigator
First posted
Oct 10, 2023
Start date
Nov 17, 2023
Primary completion
Mar 31, 2025
Completion
May 30, 2025
Last update
Sep 29, 2026

Study contacts

Christin Ellermann, MSc
principal investigator · Harding Center for Risk Literacy
Felix G. Rebitschek, Dr.
principal investigator · Harding Center for Risk Literacy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion